We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

IVERIC Bio Inc (ISEE) Ordinary Shares

Sell:$13.09 Buy:$13.11 Change: $0.56 (4.10%)
NASDAQ:2.24%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$13.09
Buy:$13.11
Change: $0.56 (4.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$13.09
Buy:$13.11
Change: $0.56 (4.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IVERIC bio, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company's therapeutics portfolio consists of Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, a high-temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor. The Company's gene therapy portfolio consists of two product candidates in pre-clinical development, IC-100 and IC-200. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Contact details

Address:
5 Penn Plaza, Suite 2372
NEW YORK
10001
United States
Telephone:
+1 (212) 8458200
Website:
https://ivericbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ISEE
ISIN:
US46583P1021
Market cap:
$1.57 billion
Shares in issue:
114.64 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Pravin Dugel
    President
  • Glenn Sblendorio
    Chief Executive Officer, Director
  • David Carroll
    Chief Financial Officer, Senior Vice President, Treasurer
  • Keith Westby
    Chief Operating Officer, Senior Vice President
  • Anthony Gibney
    Executive Vice President, Chief Business and Strategy Officer
  • Christopher Simms
    Senior Vice President, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.